Systemic Mastocytosis – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Systemic Mastocytosis – Pipeline Review, H1 2017’, provides an overview of the Systemic Mastocytosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic Mastocytosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Mastocytosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Systemic Mastocytosis

The report reviews pipeline therapeutics for Systemic Mastocytosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Systemic Mastocytosis therapeutics and enlists all their major and minor projects

The report assesses Systemic Mastocytosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Systemic Mastocytosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Systemic Mastocytosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Systemic Mastocytosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

AbbVie Inc

Arog Pharmaceuticals Inc

Blueprint Medicines Corp

Bristol-Myers Squibb Company

Deciphera Pharmaceuticals LLC

Novartis AG

Patara Pharma Inc

Seattle Genetics Inc

Stemline Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Systemic Mastocytosis - Overview

Systemic Mastocytosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Systemic Mastocytosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Systemic Mastocytosis - Companies Involved in Therapeutics Development

AB Science SA

AbbVie Inc

Arog Pharmaceuticals Inc

Blueprint Medicines Corp

Bristol-Myers Squibb Company

Deciphera Pharmaceuticals LLC

Novartis AG

Patara Pharma Inc

Seattle Genetics Inc

Stemline Therapeutics Inc

Systemic Mastocytosis - Drug Profiles

AK-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLU-285 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brentuximab vedotin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crenolanib besylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cromolyn sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dasatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCC-2618 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibrutinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

masitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

midostaurin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Systemic Mastocytosis - Discontinued Products

Systemic Mastocytosis - Product Development Milestones

Featured News & Press Releases

Mar 27, 2017: Blueprint Medicines to Present on BLU-285 at Upcoming Scientific Conferences

Jan 09, 2017: AB Science announces publication in The Lancet of phase 3 clinical trial results demonstrating masitinib is effective and well tolerated in the treatment of adult patients with severe indolent systemic mastocytosis

Dec 04, 2016: Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis

Dec 01, 2016: AB Science will present phase 3 results in severe s ystemic mastocytosis at the Journées Dermatologiques de Paris 2016

Nov 14, 2016: Novartis drug PKC412 (midostaurin) C for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis

Nov 03, 2016: Blueprint Medicines to Present Preliminary Data from Ongoing Phase 1 Clinical Trial for BLU-285 in Advanced Systemic Mastocytosis at 2016 ASH Annual Meeting

Oct 31, 2016: Deciphera Pharmaceuticals to Present Clinical Data on DCC-2618 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 28, 2016: Blueprint Medicines to Present Preclinical Data and Provide Enrollment Updates for Phase 1 Clinical Trial for BLU-285 in Advanced Systemic Mastocytosis at ECNM Annual Meeting 2016

Sep 15, 2016: Allakos Begins Clinical Trials of AK002 in Patients with Systemic Mastocytosis

Jun 29, 2016: Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM)

May 30, 2016: AB Science will Present Phase 3 Data in Severe Systemic Mastocytosis at the International 21St Congress of the European Hematology Association

May 02, 2016: AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis

Feb 01, 2016: AB Science announces that Rapporteurs appointed by the EMA have recommended to file a marketing authorization application for full approval for masitinib in severe systemic mastocytosis

Dec 07, 2015: AB Science announces results from Phase 3 randomized placebo-controlled trial of masitinib in adults with severe systemic mastocytosis unresponsive to optimal symptomatic treatment

Nov 30, 2015: AB Science Announces Positive Top-Line Results from Phase 3 Trial of Masitinib in Adults with Severe Systemic Mastocytosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Systemic Mastocytosis, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Systemic Mastocytosis – Pipeline by AB Science SA, H1 2017

Systemic Mastocytosis – Pipeline by AbbVie Inc, H1 2017

Systemic Mastocytosis – Pipeline by Arog Pharmaceuticals Inc, H1 2017

Systemic Mastocytosis – Pipeline by Blueprint Medicines Corp, H1 2017

Systemic Mastocytosis – Pipeline by Bristol-Myers Squibb Company, H1 2017

Systemic Mastocytosis – Pipeline by Deciphera Pharmaceuticals LLC, H1 2017

Systemic Mastocytosis – Pipeline by Novartis AG, H1 2017

Systemic Mastocytosis – Pipeline by Patara Pharma Inc, H1 2017

Systemic Mastocytosis – Pipeline by Seattle Genetics Inc, H1 2017

Systemic Mastocytosis – Pipeline by Stemline Therapeutics Inc, H1 2017

Systemic Mastocytosis – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Systemic Mastocytosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports